ADVERTISEMENT

Metastatic breast cancer: trastuzumab deruxtecan outperforms trastuzumab emtansine in DESTINY-Breast03

Miriam Davis, PhD   |   Clinical Summary   |   30 March 2022
ADVERTISEMENT

Takeaway

  • The antibody-drug conjugate trastuzumab deruxtecan (the latter a topoisomerase inhibitor) reduces risk of progression by a striking 72% over trastuzumab emtansine in patients whose metastatic HER2 + breast cancer has progressed after treatment with front-line anti-HER2 antibodies and a taxane, according to the DESTINY-Breast03 trial.

Why this matters

  • Findings...

          

September Challenge

Ends in 7d 4h
left
right

Topic Challenges

left
right